Showing results (1081-1090 of 1,153) with videos related to

Sort By:
Pageof 116
Blood Cancer Journal|April 24, 2025
Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA studyClémentine Sarkozy, Loïc Chartier, Vincent Ribrag, et al.
Science Advances|August 21, 2024
A20 haploinsufficiency disturbs immune homeostasis and drives the transformation of lymphocytes with permissive antigen receptorsChristoph Schultheiß, Lisa Paschold, Alma Nazlie Mohebiany, et al.
Blood|April 14, 2011
Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adultsItziar Salaverria, Claudia Philipp, Ilske Oschlies, et al.
Leukemia|May 15, 2007
A comprehensive genetic and histopathologic analysis identifies two subgroups of B-cell malignancies carrying a t(14;19)(q32;q13) or variant BCL3-translocationJ I Martín-Subero, R Ibbotson, W Klapper, et al.
Cancer Research|April 20, 2019
MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt LymphomaJennifer Hüllein, Mikołaj Słabicki, Maciej Rosolowski, et al.
Nature Communications|January 2, 2025
Integrating genetic subtypes with PET scan monitoring to predict outcome in diffuse large B-cell lymphomaMatías S Mendeville, Jurriaan Janssen, G Tjitske Los-de Vries, et al.
Journal of Hematopathology|August 12, 2009
Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL NetworkWolfram Klapper, Eva Hoster, Olaf Determann, et al.
Blood|April 8, 2024
Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphomaEmma Kroeze, Ingram Iaccarino, Michelle M Kleisman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2023
Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient OutcomesDaniel Noerenberg, Franziska Briest, Cornelius Hennch, et al.
Leukemia|April 27, 2024
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma networkLuca Fischer, Linmiao Jiang, Jan Dürig, et al.
Pageof 116